FAYETTEVILLE, Ark. - PRDelivery -- FAYETTEVILLE, Ark. – Lineus Medical announces the completion of a $4.579 million Series C funding round. The Series C round allowed Lineus Medical to expand its sales and clinical education team, secure international regulatory clearances, and obtain additional U.S. and international patents which positions the organization for continued growth and expansion. Since its founding in 2015, Lineus Medical has raised a total of $11.5 million, supporting the continued development and commercialization of its flagship product, SafeBreak® Vascular.

SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications¹.  When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money¹.

More on PR Delivery

• Rampage Jackson and Rashad Evans Face Off At Press Conference At The Palms Casino Resort in Las Vegas on March 20, 2025
• Drone Light Shows Become the Must-Have Entertainment Trend for Events and Venues
• Multi-Million Dollar Contracts and Key Partnerships for Cybersecurity Solutions in the Rapidly Growing Market Nearing $200 Billion Annually $CYCU
• Unveil Hydrogen-Powered Maritime Innovation at H2Hub Summit
• Brookline Family Dentistry Updates Website URL for a Stronger Brand Identity

Vance Clement, Lineus Medical's CEO stated, "Our investors have seen us through the trials and tribulations of starting a medical device business, obtaining FDA De Novo clearance for a new class of product, and completing several successful clinical trials. We continue to gain customers and gain market traction. We thank our investors for their support through the pandemic and over the past three years, which has been a very difficult market to raise funds. Our investors believe, as does the Lineus Medical team, that this is only the beginning. We will continue to strive to make break-away devices the new standard of care for IV lines, and SafeBreak the preferred choice of nurses around the world.

We would also like to thank the hospitals and nurses that are our customers. Without you, we are nothing. You are the early adopters and the innovators that show your patients that you care by reducing needlesticks and IV restarts. It takes vision, guts and determination to evaluate and bring new technology into your hospital.  We thank you.

More on PR Delivery

• Major Defense Contractor, Satellite and Multiple Deployable Tech Companies Partnering with Ascent Solar Technologies, Inc: Stock Symbol: ASTI
• Rosann Santos Ofrece el Programa Repensando el Síndrome del Impostor™
• Criptlán Partners with Top Capital and Technology Teams to Drive the Future of the Digital Economy
• From Sea to the Site: The Evolution of the Shipping Container From the Water to the Worksite
• Inbound Lead Generation for Security Companies in 2025: The Key to Sustainable Growth

With these funds, we will continue to expand our customer base, lower the manufacturing cost and price of our product, and conduct clinical research showing the value of break-away devices for all types of IV lines and patients of all ages."

About Lineus Medical:

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications¹. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

References:
1. Data on File